Zivo Bioscience, Inc. · OTC:ZIVO

Zivo Bioscience — Dawon James Small Cap Growth Conference (October 2023)

13 slides from Zivo Bioscience's conference presentation, October 2023

1. Slide 1: Transformative Opportunities in Therapeutics & Nutrition

   (Nasdaq: ZIVO) Transformative Opportunities in Therapeutics & Nutrition October 2023

2. Slide 2: Disclaimer

   Disclaimer SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS Some of the statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These sta

3. Slide 3: Investment Overview

   Investment Overview One Natural Source. Numerous Commercial Opportunities. Developing novel therapeutics and functional food ingredients to power immune health Currently Generating Revenue • DTC launch in June 2023 of Zivolife™, a nutritional supplement for the human green powder and vegan protein m

4. Slide 4: ZIVO Bioscience At-a-Glance

   ZIVO Bioscience At-a-Glance Nutrition (agtech) Therapeutics (biotech) • Growth and distribution of Zivolife, ZIVO’s • Identification and development of extracts, fractions proprietary whole algal biomass, for use as or molecules derived from proprietary algal a food or food ingredient to leverage it

5. Slide 5: Zivolife – Proprietary Algal Biomass

   Zivolife™ – Proprietary Algal Biomass Our first revenue-generating, commercially-available product $247 million TAM by 2033 Global food & beverage microalgae market Background  Zivolife is natural, non-GMO and a source of plant-based protein, naturally occurring beta glucan and fiber  Sustainable,

6. Slide 6: Committed Revenue Stream Grows with Scale

   Committed Revenue Stream Grows with Scale 24,000 kg annual purchase commitment1 ZWorldwide is ZIVO’s global distribution partner, Algae production ponds with an initial focus on North America  Commits to minimum annual volume purchases for 5 years  ZWorldwide to purchase entire Zivolife supply for

7. Slide 7: Significant Market Opportunity in Nutrition

   Significant Market Opportunity in Nutrition Proprietary dried algal biomass as a food or food ingredient Nutritive compounds found in ZIVO algae include functional food ingredients proven to enhance overall health in humans Market Opportunity Cultivation Model $6.3 billion in 2021  Presently growin

8. Slide 8: Significant Market Opportunity in Therapeutics

   Significant Market Opportunity in Therapeutics Bioproducts from Zivo proprietary assets feature broad therapeutic potential in animals and humans. Initial Commercial Application Market Opportunity  Coccidiosis treatment designed to be introduced in poultry feed or drinking water - IP protected via

9. Slide 9: Validated Efficacy in Poultry through Numerous Studies

   Validated Efficacy in Poultry through Numerous Studies More than 20 independent research trials to evaluate the efficacy of ZIVO’s bioactive compounds in the treatment of coccidiosis have been completed Validated efficacy and mechanism-of-action studies in poultry gut health  Minimize or eliminate

10. Slide 10: Additional Therapeutic Opportunities

    Additional Therapeutic Opportunities ZIVO will expand products/technology into other therapeutic opportunities, and employ a business model to license proprietary molecules or bioproducts to monetize its intellectual property portfolio Poultry Other (Livestock) Porcine (Livestock) Bovine (Livestock)

11. Slide 11: Where ZIVO is Headed

    Where ZIVO is Headed Biotech Molecules AgTech Algal Biomass Extracts Biotechnology Compounds Agricultural Technology Dry Mixes Complexes Poultry Digestive Health Strategic Partnerships & Regional Distributors  Prospective licensing or joint development deal  Establish regional distributorships  C

12. Slide 12: Leadership Team

    Leadership Team John B. Payne – President and CEO Harlan L. Miller III, PhD – VP Technology and Global Supply Served on ZIVO’s Board since 2013 and Chairman since 2019. He Dr. Miller is a recognized expert in algal production systems, has a significant management experience in publicly-traded previo

13. Slide 13: Investment Overview

    Investment Overview One Natural Source. Numerous Commercial Opportunities. Developing novel therapeutics and functional food ingredients to power immune health Currently Generating Revenue • DTC launch in June 2023 of Zivolife™, a nutritional supplement for the human green powder and vegan protein m

ZIVO Bioscience — Dawon James Small Cap Growth Conference (October 2023) on 6ix